Inflammation and Heart Stress Peptides Are Elevated in Fabry Disease, Pointing to Heart Failure Mechanisms | Research

The takeaway

Fabry disease patients show elevated inflammatory biomarkers and natriuretic peptides that correlate with cardiac damage severity, consistent with inflammation-driven heart failure.

12 biomarkers elevated
Fabry disease patients showed significantly higher levels of inflammatory markers, natriuretic peptides, and matrix metalloproteases vs. healthy controls

What the researchers found

Patients with Fabry disease showed significantly elevated levels of multiple inflammatory and cardiac remodeling biomarkers compared to healthy controls, including the natriuretic peptides BNP and MR-pro ANP, matrix metalloproteases (MMP-2, MMP-9), TNF, TNFR1, TNFR2, IL-6, galectin-1, and globotriaosylsphingosine.

Key biomarker correlations included: TNFR2, TNF, IL-6, MMP-2, and globotriaosylsphingosine were elevated in patients with left ventricular hypertrophy; BNP, MR-pro ANP, and MMP-2 correlated with diastolic dysfunction; and patients with cardiac scarring (late gadolinium enhancement on MRI) had higher BNP, MR-pro ANP, TNFR1, TNFR2, and MMP-2. These findings support a phenotype dominated by heart failure with preserved ejection fraction driven by systemic inflammation.

Why it matters

Fabry disease is a rare genetic condition that progressively damages the heart, kidneys, and nervous system. This study identifies a specific pattern of inflammatory and natriuretic peptide biomarkers that track with disease severity, potentially enabling better monitoring and earlier intervention. The connection to HFpEF pathophysiology through inflammation may also inform treatment strategies.

The numbers in context

n=68 Fabry patients vs n=40 controls · 12 biomarkers measured · Multiple significant correlations with cardiac imaging · Multicenter cohort

How the study worked

Multicenter observational study comparing plasma levels of 12 inflammatory and cardiac remodeling biomarkers between 68 Fabry disease patients and 40 healthy controls. Biomarker levels were correlated with clinical profile, cardiac MRI (including late gadolinium enhancement), and echocardiographic findings including diastolic function and left ventricular hypertrophy.

Who was studied

68 patients with Fabry disease and 40 healthy controls from multicenter cohorts

What this study cannot tell us

Cross-sectional design cannot establish causation between inflammation and cardiac dysfunction. Relatively small sample size (68 patients) for a condition with heterogeneous presentation. The study cannot determine whether elevated biomarkers are causes or consequences of cardiac involvement in Fabry disease.

How to read the evidence

Multicenter observational study with appropriate controls and comprehensive biomarker panel correlated with cardiac imaging. The sample size is reasonable for a rare disease, though cross-sectional design limits causal inference.

When this study was published

Published in 2018, this study established important biomarker-phenotype correlations in Fabry cardiomyopathy that continue to inform clinical monitoring and research directions.

The bigger picture

Understanding that Fabry cardiomyopathy involves systemic inflammation and follows a HFpEF phenotype could shift treatment approaches from enzyme replacement alone to include anti-inflammatory strategies. The natriuretic peptide elevations also provide clinicians with accessible blood tests for monitoring cardiac involvement and treatment response.

Questions still open

Could anti-inflammatory therapies complement enzyme replacement therapy in Fabry disease cardiac management?
Can serial natriuretic peptide measurements predict cardiac progression in Fabry disease before imaging changes appear?
Do newer Fabry treatments (substrate reduction, gene therapy) normalize these inflammatory biomarker profiles?

Common questions

What is Fabry disease and how does it affect the heart?

Fabry disease is a rare inherited condition where a missing enzyme causes fatty substances to accumulate in cells throughout the body. In the heart, this leads to thickening of the walls, stiffness, and eventually heart failure. This study showed that chronic inflammation plays a key role in driving this cardiac damage.

What are natriuretic peptides and what do they indicate?

BNP and MR-pro ANP are peptide hormones released by the heart when it's under stress. Elevated levels indicate that the heart is working harder than normal and can signal heart failure. In Fabry disease, elevated natriuretic peptides correlated with specific cardiac damage seen on MRI imaging.

Read the original research

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.

Journal of the American Heart Association, 7(21), e009098

View on PubMed ↗Publisher’s paper ↗

Citation

Yogasundaram, Haran; Nikhanj, Anish; Putko, Brendan N; Boutin, Michel; Jain-Ghai, Shailly; Khan, Aneal; Auray-Blais, Christiane; West, Michael L; Oudit, Gavin Y. (2018). Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction.. Journal of the American Heart Association, 7(21), e009098. https://doi.org/10.1161/JAHA.118.009098